| Note | |
| | |
| Entity | Various cancers |
| Note | MCT1/SLC16A1 has been described to be upregulated in a variety of tumours. |
| Disease | High grade glial neoplasms (Mathupala et al., 2004; Fang et al., 2006), colorectal (Koukourakis et al., 2006; Pinheiro et al., 2008), lung (Koukourakis et al., 2007), cervical (Pinheiro et al., 2008), and breast carcinomas (Pinheiro et al., in Press). |
| | |
| | |
| Entity | Breast cancer |
| Prognosis | In breast cancer, MCT1/SLC16A1 was found to be associated with poor prognostic variables such as basal-like subtype and high grade tumours (Pinheiro et al., in Press). |
| Oncogenesis | SLC16A1 is expressed in normal breast tissue, but is silenced in breast cancer due to gene methylation (Asada et al., 2003). |
| | |
| | |
| Entity | Gastric cancer |
| Note | The prognostic value of CD147 (a MCT1/SLC16A1 and MCT4/SLC16A3 chaperone required for plasma membrane expression and activity) was associated with MCT1/SLC16A1 co-expression in gastric cancer cells (Pinheiro et al., 2009). |
| Prognosis | Co-expression of MCT1/SLC16A1 with CD147 was associated with advanced gastric carcinoma, Lauren's intestinal type, TNM staging and lymph-node metastasis, in gastric cancer. |
| | |
| | |
| Entity | Colorectal carcinoma |
| Note | MCT1/SLC16A1 has been described to be downregulated in colorectal carcinoma (Lamber et al., 2002). |
| | |
| | |
| Entity | Erythrocyte lactate transporter defect |
| Note | Merezhinskaya et al. (2000) identified two heterozygous transitions in the SLC16A1 gene, in patients with erythrocyte lactate transporter defect: 610A-G transition (resulting in a lys204-to-glu (K204E) substitution in a highly conserved residue) and 1414G-A transition (resulting in a gly472-to-arg (G472R) substitution halfway along the cytoplasmic C-terminal chain). These substitutions are not conserved, but were not identified in 90 healthy control individuals. Erythrocyte lactate clearance in patients with these mutations was 40 to 50% that of normal control values. |
| | |
| | |
| Entity | Hyperinsulinemic hypoglycemia familial 7 |
| Note | Otonkoski et al. (2007) identified two heterozygotic alterations in the SLC16A1, in affected members of a Finnish family segregating autosomal dominant exercise-induced hyperinsulinemic hypoglycemia. First, a 163G-A transition in exon 1 located within a binding site for nuclear matrix protein-1 and predicted to disrupt the binding sites of 2 potential transcriptional repressors, and, secondly, a 25-bp insertion at nucleotide -24 introducing additional binding sites for the ubiquitous transcription factors SP1, USF and MZF1. The first variation leads to a 3-fold increase in transcription while the second variation leads to a 10-fold increase in transcription. These mutations were not found in 92 Finnish and German controls. |
| | |
| Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. |
| Asada K, Miyamoto K, Fukutomi T, Tsuda H, Yagi Y, Wakazono K, Oishi S, Fukui H, Sugimura T, Ushijima T. |
| Oncology. 2003;64(4):380-8. |
| PMID 12759536 |
| |
| Cardiac and skeletal muscle mitochondria have a monocarboxylate transporter MCT1. |
| Brooks GA, Brown MA, Butz CE, Sicurello JP, Dubouchaud H. |
| J Appl Physiol. 1999 Nov;87(5):1713-8. |
| PMID 10562613 |
| |
| The human monocarboxylate transporter, MCT1: genomic organization and promoter analysis. |
| Cuff MA, Shirazi-Beechey SP. |
| Biochem Biophys Res Commun. 2002 Apr 12;292(4):1048-56. |
| PMID 11944921 |
| |
| The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. |
| Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML. |
| Mol Pharmacol. 2006 Dec;70(6):2108-15. Epub 2006 Sep 25. |
| PMID 17000864 |
| |
| cDNA cloning of the human monocarboxylate transporter 1 and chromosomal localization of the SLC16A1 locus to 1p13.2-p12. |
| Garcia CK, Li X, Luna J, Francke U. |
| Genomics. 1994 Sep 15;23(2):500-3. |
| PMID 7835905 |
| |
| The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. |
| Halestrap AP, Meredith D. |
| Pflugers Arch. 2004 Feb;447(5):619-28. Epub 2003 May 9. (REVIEW) |
| PMID 12739169 |
| |
| Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. |
| Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E. |
| Cancer Biol Ther. 2007 Sep;6(9):1476-9. Epub 2007 Jun 27. |
| PMID 17881895 |
| |
| Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. |
| Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP. |
| Br J Cancer. 2002 Apr 22;86(8):1262-9. |
| PMID 11953883 |
| |
| Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. |
| Mathupala SP, Parajuli P, Sloan AE. |
| Neurosurgery. 2004 Dec;55(6):1410-9; discussion 1419. |
| PMID 15574223 |
| |
| Peroxisomal membrane monocarboxylate transporters: evidence for a redox shuttle system? |
| McClelland GB, Khanna S, Gonzalez GF, Butz CE, Brooks GA. |
| Biochem Biophys Res Commun. 2003 Apr 25;304(1):130-5. |
| PMID 12705896 |
| |
| Mutations in MCT1 cDNA in patients with symptomatic deficiency in lactate transport. |
| Merezhinskaya N, Fishbein WN, Davis JI, Foellmer JW. |
| Muscle Nerve. 2000 Jan;23(1):90-7. |
| PMID 10590411 |
| |
| Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. |
| Otonkoski T, Jiao H, Kaminen-Ahola N, Tapia-Paez I, Ullah MS, Parton LE, Schuit F, Quintens R, Sipila I, Mayatepek E, Meissner T, Halestrap AP, Rutter GA, Kere J. |
| Am J Hum Genet. 2007 Sep;81(3):467-74. Epub 2007 Jul 26. |
| PMID 17701893 |
| |
| Monocarboxylate transporter 1 is upregulated in basal-like breast carcinoma. |
| Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F. |
| Histopathology In press |
| |
